<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ZICONOTIDE</span><br/>zi-con'o-tide<br/><span class="topboxtradename">Prialt<br/></span><b>Classifications:</b> <span class="classification">nonnarcotic analgesic</span>; <span class="classification">n-type calcium channel blocker</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mcg/mL and 100 mcg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Ziconotide binds to N-type calcium channels located on the afferent nerves in the dorsal horn in the spinal cord. It is thought
         that these binding blocks of N-type calcium channels lead to a blockade of excitatory neurotransmitter release in the afferent
         nerve endings.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Ziconotide is effective in controlling severe chronic pain that is intractable to other analgesics.</p>
<h1><a name="uses">Uses</a></h1>
<p>Management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Spasticity associated with spinal cord trauma.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ziconotide; preexisting history of psychosis; depression with suicidal ideation; cognitive impairment;
         presence of infection at the injection site, uncontrolled bleeding, or spinal canal obstruction that impairs circulation of
         CSF; lactation. Safety and efficacy in children not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Elderly; renal, hepatic, and cardiac impairment; concurrent use of CNS depressant(s); pregnancy (category C).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Severe Chronic Pain</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Intrathecal</span> Initial 0.1 mcg/h; may titrate up <img src="../images/special/lesserorequal.gif"/> 0.1 mcg/h q23d to 0.8 mcg/h (19.2
               mcg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intrathecal</span><br/><ul>
<li>May be administered undiluted (25 mcg/mL in 20 mL vial) or diluted using the 100 mcg/mL vials. Diluted ziconotide is prepared
            with NS without preservatives.
         </li>
<li>Administer using an implanted variable-rate microinfusion device or an external microinfusion device and catheter.</li>
<li>Note: Due to serious adverse events, 19.2 mcg/d (0.8 mcg/h) is the maximum recommended dose.</li>
<li>Doses should normally be titrated upward by no more than 2.4 mcg/d (0.1 mcg/h) at intervals of 23 times/wk.</li>
<li>Refrigerate all ziconotide solutions after preparation and begin infusion within 24 h. Discard any unused portion left in
            a vial.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">
<b></b>Body as a Whole:</span> Accidental injury, back pain, catheter complication, catheter-site pain, cellulitis, chest pain, chills, <span class="speceff-common">fever,</span> flu syndrome, infection, malaise, neck pain, neck rigidity, <span class="speceff-common">pain,</span> pump-site complication, pump-site mass, pump-site pain, viral infection. <span class="typehead">CNS:</span> Abnormal dreams, <span class="speceff-common">abnormal gait,</span> agitation, <span class="speceff-common">anxiety, aphasia, asthenia, ataxia,</span> CSF abnormal, <span class="speceff-common">confusion,</span> depression, difficulty concentrating, <span class="speceff-common">dizziness,</span> dry mouth, <span class="speceff-common">dysesthesia,</span> emotional lability, <span class="speceff-common">headache,</span> hostility, hyperesthesia, <span class="speceff-common">hypertonia,</span> incoordination, insomnia, <span class="speceff-common">memory impairment,</span> mental slowing, meningitis, <span class="speceff-common">nervousness,</span> neuralgia, paranoid reaction, <span class="speceff-common">paresthesia,</span> reflexes decreased, <span class="speceff-common">somnolence, speech disorder,</span> stupor, abnormal thinking, tremor, twitching, <span class="speceff-common">vertigo.</span>
<span class="typehead">CV:</span> Hypertension, hypotension, postural hypotension, syncope, tachycardia, vasodilation. <span class="typehead">GI:</span> Abdominal pain, <span class="speceff-common">anorexia,</span> constipation, <span class="speceff-common">diarrhea,</span> dyspepsia, gastrointestinal disorder, <span class="speceff-common">nausea, vomiting</span>. <span class="typehead">GU:</span> Dysuria, urinary incontinence, <span class="speceff-common">urinary retention,</span> urinary tract infection, impaired urination. <span class="typehead">Hematologic:</span> Anemia, ecchymosis.  <span class="typehead">Metabolic/Nutritional:</span> Creatinine phosphokinase increased, dehydration, edema, hypokalemia, peripheral edema, weight loss. <span class="typehead">Musculoskeletal:</span> Arthralgia, arthritis, leg cramps, myalgia, myasthenia. <span class="typehead">Respiratory:</span> Bronchitis, cough increased, dyspnea, lung disorder, pharyngitis, pneumonia, rhinitis, sinusitis. <span class="typehead">Skin:</span> Cutaneous surgical complication, dry skin, pruritus, rash, skin disorder, sweating. <span class="typehead">Special Senses:</span>
<span class="speceff-common">Abnormal vision,</span> diplopia, <span class="speceff-common">nystagmus,</span> photophobia, taste perversion, tinnitus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Ethanol</b> and other <span class="classification">cns depressants</span> may increase drowsiness, dizziness, and confusion, if given with ziconotide. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> 50% protein bound. <span class="typehead">Metabolism:</span> Hydrolyzed by peptidases. <span class="typehead">Half-Life:</span> 4.6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and report S&amp;S of meningitis, cognitive impairment, hallucinations, changes in mood or consciousness, or other
            psychiatric symptoms.
         </li>
<li>Lab tests: Serum creatine kinase every other week for first month and monthly thereafter.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following to physician: muscle pain, soreness, or weakness, confusion, unusual behavior, symptoms of depression
            or suicidal thoughts, fever, headache, stiff neck, nausea or vomiting, seizures.
         </li>
<li>Note: Taking this drug with other depressants (e.g., alcohol, sedatives, tranquilizers) will increase the risk of side effects.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>